Recall of E1-Tapered 10 degree +3mm Liner 32/39 (hip joint prosthesis, acetabular component)

According to Department of Health, Therapeutic Goods Administration, this recall involved a device in Australia that was produced by Biomet Australia Pty Ltd.

What is this?

A correction or removal action taken by a manufacturer to address a problem with a medical device. Recalls occur when a medical device is defective, when it could be a risk to health, or when it is both defective and a risk to health.

Learn more about the data here
  • Type of Event
    Recall
  • Event ID
    RC-2012-RN-00813-3
  • Event Risk Class
    Class II
  • Event Initiated Date
    2012-08-09
  • Event Country
  • Event Source
    DHTGA
  • Event Source URL
  • Notes / Alerts
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • Extra notes in the data
  • Reason
    Biomet spain orthopaedics s.L. has initiated this action following the investigation on a reported event. it has been confirmed that in a few cases the affected product does not properly fit in the acetabular cup.
  • Action
    Biomet Australia is contacting the treating/implanting surgeon regarding the issue so that the affected patient can be appropriately managed.

Device

  • Model / Serial
    E1-Tapered 10 degree +3mm Liner 32/39 (hip joint prosthesis, acetabular component)Product Part Number: E1-103239Lot Number: 2011010452ARTG Number: 120149
  • Manufacturer

Manufacturer

  • Manufacturer Parent Company (2017)
  • Manufacturer comment
    “The safety of patients has always been, and continues to be, Zimmer Biomet’s top priority and it is our honor to be a leader in this industry for the past 90 years,” Zimmer Biomet told ICIJ in a statement. “We adhere to strict regulatory standards, and work closely with the FDA and all applicable regulatory agencies in each of our regions as part of our commitment to operating a first-rate quality management system across our global manufacturing network. The company added that it is focused on staying at the forefront of innovation and doing right by the millions of patients who rely on the company’s products.
  • Source
    DHTGA